文献速递头颈部肿瘤放疗

头颈癌患者强化治疗选择的ω评分验证与合并症影响

Selection of Head and Neck Cancer Patients for Intensive Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-09-30

本研究基于7117例美国退伍军人头颈癌放疗患者,验证临床试验数据开发的ω评分列线图可按癌症进展与竞争死亡的相对风险分层。合并症、当前吸烟、低BMI和年龄增长与ω+比值降低相关。

要点

  • ω评分可有效分层头颈癌放疗患者的复发与竞争死亡相对风险。
  • 合并症指数≥2、当前吸烟、低BMI和年龄增长与ω+比值降低相关。

核心结论

  • ω评分可有效分层头颈癌患者,并与治疗强度相关。
  • 整合合并症和其他风险因素的ω评分有助于识别最可能从强化治疗中获益的头颈癌患者。

研究设计与样本

  • 基于7117例美国退伍军人头颈癌放疗患者的队列研究。
  • 评估临床试验数据开发的ω评分列线图对癌症进展与竞争死亡相对风险的分层能力。
  • 采用广义竞争事件模型分析合并症及其他协变量对ω+比值的影响。

主要发现

  • ω评分可有效分层头颈癌患者的癌症复发相对竞争死亡风险,尤其在年龄>70岁患者中。
  • 多变量分析中,T2-4类别(RHR 1.08,95%CI 1.01-1.16)、N2-3类别(RHR 1.07,95%CI 1.01-1.15)和在职状态(RHR 1.11,95%CI 1.03-1.20)与ω+比值升高相关。
  • 年龄增长(RHR 0.83,95%CI 0.78-0.89)、Charlson合并症指数≥2(RHR 0.85,95%CI 0.79-0.91)、当前吸烟(RHR 0.90,95%CI 0.84-0.96)和较低体重指数(RHR 0.89,95%CI 0.84-0.95)与ω+比值降低相关。

临床怎么用

  • 可利用ω评分列线图辅助评估头颈癌患者复发风险与竞争死亡风险的相对关系。
  • 在临床决策中应考虑合并症、吸烟状态、体重指数和年龄等因素对ω+比值的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Previous studies have found that patients with head and neck cancer (HNC) with a higher relative hazard for recurrence versus competing mortality (ω+ ratio) are more likely to benefit from intensive therapy. Nomograms to predict this ratio (ω scores) can be useful to guide clinical management; however, comorbidity and other risk factors are frequently lacking from trial samples. METHODS AND MATERIALS: In this study of 7117 US veterans, we evaluated the ability of a ω score nomogram developed from clinical trial data to stratify patients with HNC treated with radiation therapy by their relative risk of cancer progression versus competing mortality. We then fit generalized competing event models to determine the effect of comorbidity and other covariates on the ω+ ratio. RESULTS: The ω score was effective in stratifying patients with HNC according to their risk for cancer recurrence relative to competing mortality, especially among patients aged >70 years. Patients with ω score ≥0.80 were more likely to receive intensive therapy compared with patients with a ω score <0.80 (66 vs. 54%; P < .001). On multivariable generalized competing event regression, T2-4 category (relative hazard ratio [RHR], 1.08; 95% confidence interval [CI], 1.01-1.16), N2-3 category (RHR, 1.07; 95% CI, 1.01-1.15), and being employed (RHR, 1.11; 95% CI, 1.03-1.20) were associated with increased ω+ ratio, and increasing age (RHR, 0.83; 95% CI, 0.78-0.89), Charlson comorbidity index ≥2 (RHR, 0.85; 95% CI, 0.79-0.91), being a current smoker (RHR, 0.90; 95% CI, 0.84-0.96), and lower body mass index (RHR, 0.89; 95% CI, 0.84-0.95) were associated with a decreased ω+ ratio. CONCLUSIONS: The ω scores are effective in stratifying patients with HNC and are correlated with the intensity of treatment given. The ω scores incorporating comorbidity and other risk factors could help identify patients with HNC most likely to benefit from intensive therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Vitzthum LK, Park H, Zakeri K, et al. Selection of Head and Neck Cancer Patients for Intensive Therapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 31580929. doi:10.1016/j.ijrobp.2019.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。